Suchergebnisse - "Manzoor, Beenish S"

PubPharm (23)

1

Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting

enthalten in: JCO oncology practice | 2024

von Fakhri, B. | Emechebe, N. | Manzoor, B. | +4

2

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

enthalten in: Leukemia & lymphoma | 2023

von Huntington, S. | Manzoor, B. | Puckett, J. | +5

3

Updated quality of life data from the phase 3b VENICE II trial : patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy

enthalten in: Leukemia & lymphoma | 2023

von Cochrane, T. | Enrico, A. | Gomez-Almaguer, D. | +12

4

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings : Results From a Multi-Center International Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Shadman, M. | Manzoor, B. | Sail, K. | +28

5

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada

enthalten in: PharmacoEconomics - open | 2023

von Chatterjee, A. | van de Wetering, G. | Goeree, R. | +5

6

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada

enthalten in: PharmacoEconomics - open | 2022

von Chatterjee, A. | van de Wetering, G. | Goeree, R. | +5

7

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

enthalten in: Blood advances | 2022

von Thompson, M. | Harrup, R. | Coombs, C. | +35

8

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

enthalten in: Journal of managed care & specialty pharmacy | 2021

von Chatterjee, A. | Shapouri, S. | Manzoor, B. | +5

9

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States

enthalten in: PharmacoEconomics | 2020

von Cho, S. | Manzoor, B. | Sail, K. | +8

10

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States

enthalten in: PharmacoEconomics | 2020

von Cho, S. | Manzoor, B. | Sail, K. | +8